Cantourage
- Company typePublic
- Founded2019
- HeadquartersBerlin, Germany
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Cantourage does
Cantourage is a Berlin-based European medical cannabis company founded in 2019 and listed on the Frankfurt Stock Exchange (ticker HIGH) since November 2022. The company operates an asset-light platform that imports dried cannabis flowers from a network of 60+ cultivation partners across 18 countries, processes them to EU-GMP pharmaceutical standards at facilities in Germany and Portugal, and distributes the finished pharmaceutical-grade products to pharmacies across 8 European markets (Germany, UK, Austria, Switzerland, Poland, Czech Republic, Denmark). Cantourage also produces and distributes cannabis extracts, dronabinol (pure THC), and CBD products.
Its core technology is the Fast Track Access platform, a proprietary system that consolidates the complex, multi-step process of bringing international cannabis raw materials into European pharmaceutical compliance — handling import, trimming, microbiological reduction, packaging, labelling, testing, market release, warehousing, and fulfilment. This is paired with telemedicine front-ends: Telecan in Germany and Cantourage Clinic in the UK, which enable patients to obtain cannabis prescriptions online and have them fulfilled via partner pharmacies.
Cantourage's revenue model is a transaction-fee / revenue-share arrangement: the company does not own cultivation assets but earns on the processing and distribution margin when third-party cultivators' products are sold into European pharmacies. GTM is hybrid — sales-led B2B to pharmacies and physicians across its eight markets, complemented by direct-to-patient prescription generation through its telehealth platforms. The company achieved break-even in 2023 on the strength of this asset-light structure, with revenue subsequently accelerating to EUR 92.8M (preliminary) in FY2025.
Cantourage firmographics
Firmographics- Name
- Cantourage
- Legal name
- Cantourage GmbH
- Website
- https://cantourage.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Cantourage industry classification
Industry- Product category
- Medical Cannabis Pharmaceuticals
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421), Medicinal and Botanical Manufacturing (325411)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
- akta.pro secondary industries
- Medical Cannabis Delivery & Online Ordering (CRANAGAG), Medical Cannabis Dispensaries (CRANAFAB)
Keywords
Where Cantourage is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices3 records
Markets served
Cantourage business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Cannabis flower processing and distribution: Cantourage imports cannabis flowers from its global network of 60+ cultivators in 18 countries, processes them at EU-GMP certified facilities in Germany and Portugal, and distributes pharmaceutical-grade dried cannabis flowers to pharmacies across Europe. Revenue is generated through the sale of processed cannabis flowers under a revenue-sharing model with cultivators.
- Extracts, Dronabinol and CBD: Cantourage produces and distributes extracts, dronabinol (pure THC), and Cannabidiol (CBD) products across all relevant pharmaceutical market segments. These are sold to pharmacies and healthcare providers.
- Exclusive distribution partnerships: Cantourage holds exclusive distribution rights for certain product lines including Portocanna's Hexacan brand and specific strains from cultivation partners, expanding its portfolio without additional cultivation investment.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Cantourage product offering
Product offeringCore offering
Cantourage imports cannabis raw materials from over 60 cultivation partners across 18 countries, processes them at EU-GMP certified facilities in Germany and Portugal into pharmaceutical-grade products (dried flowers, extracts, dronabinol, and CBD), and distributes them to pharmacies across eight European markets under a revenue-sharing model with cultivators. The company complements its product business with patient-facing telemedicine platforms (Telecan in Germany and Cantourage Clinic in the UK) that enable online cannabis prescriptions from experienced cannabis physicians.
Product overview
Cantourage is a European medical cannabis platform that operates a portfolio of products and services. Their core offering includes the Fast Track Access Platform enabling international cultivators to access European markets, combined with pharmaceutical-grade products across all market segments: dried cannabis flowers (imported from 60+ cultivators across 18 countries), cannabis extracts, Dronabinol (pure THC), and CBD products. The company complements its product business with telemedicine platforms (Telecan in Germany and Cantourage Clinic in the UK) that facilitate patient access to cannabis prescriptions. Distribution reaches pharmacies in Germany, the UK, Austria, Switzerland, Poland, Czech Republic, and Denmark.
Differentiator
Problem solved
Functional benefit
Brands
- Telecan: Telemedicine platform for cannabis prescriptions in Germany, enabling patients to consult with doctors and receive prescriptions online
- Cantourage Clinic
- Fast Track Access
- Hexacan
Quantifiable outcome
- Revenue of EUR 92.8 million in 2025, up from EUR 51.4 million in 2024 (118% year-over-year growth)
- +3 more outcomes
Companies that use Cantourage
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Cantourage technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Cantourage partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- PharmaVitaecorePolish pharmaceutical distributor partnership for Cantourage's cannabis products. PharmaVitae distributes Cantourage's Gelato 33 and MAC 1 strains to pharmacies across Poland. The partnership targets at least doubling sales from around 500 kg in 2025 to over 1 tonne of cannabis flowers in 2026. PharmaVitae is a Polish private company founded in 2011, specializing in import and distribution of Rx and OTC medicines, medical devices, and cosmetics. It generated PLN 80 million in revenue in 2023.
- LOT420minorCanadian cannabis cultivator supplying the Gelato 33 strain to Cantourage for distribution in Poland through the PharmaVitae partnership. LOT420 is a Canadian producer committed to providing patients with the best possible quality cannabis products.
- PortocannacoreExclusive strategic partnership with Portuguese medical cannabis processor Portocanna. Portocanna's state-of-the-art EU-GMP certified production facility serves as an additional processing site for Cantourage's cannabis flowers from 65+ cultivation partners in 18 countries, increasing Cantourage's processing capacity by up to six tons per year. The first two products (Supreme Diesel and Fiji Sunset from Green Karat) processed at Portocanna are available in German pharmacies. Additionally, Cantourage gained exclusive distribution rights for Portocanna's 'Hexacan' product line.
- Green KaratminorCultivation partner supplying cannabis strains (Supreme Diesel and Fiji Sunset) to Cantourage. Products processed at Portocanna and distributed in German pharmacies.
- Cantourage UKcoreUK subsidiary of Cantourage that distributes products to pharmacies in the United Kingdom and operates the Cantourage Clinic telehealth platform for UK patients.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
Cantourage competitors and assessment
Company assessmentBroad incumbents
- Canopy Growth: Canadian-listed multinational cannabis company with EU medical cannabis distribution. Comparable at the cross-border medical cannabis wholesale layer, though significantly larger and broader than Cantourage's platform.
- STADA Arzneimittel: German-headquartered European pharmaceutical generics and specialty company with a growing cannabis portfolio (e.g., through partnerships). Comparable as a regulated pharma distribution channel that competes for medical cannabis shelf space in German pharmacies.
- Aurora Cannabis: Canadian-listed global cannabis producer with European medical cannabis operations. Comparable as a multi-country medical cannabis wholesale supplier but with an integrated cultivation footprint that Cantourage deliberately avoids.
- Tilray Brands: Large global cannabis incumbent with established EU medical cannabis operations. Comparable to Cantourage at the wholesale/pharmacy-distribution layer but operates a much broader product and geographic portfolio at scale.
Direct peers
- Avextra: Frankfurt-based medical cannabis operator focused on EU-GMP-certified cultivation and pharmacy distribution across Germany and other European markets. Comparable as a regulated EU medical cannabis producer/distributor competing for the same pharmacy channel.
- Sanity Group: Berlin-based medical cannabis company operating in Germany across cultivation, processing, and distribution. Directly comparable to Cantourage as a fellow German-headquartered medical cannabis platform with vertically integrated pharmacy and patient access.
- Cannamedical Pharma: German medical cannabis importer and wholesaler supplying pharmacies across Germany. Directly comparable to Cantourage's wholesale pharmacy distribution model, including its multi-supplier flower portfolio strategy.
- Demecan: German medical cannabis producer and distributor serving German pharmacies. Directly comparable as a domestic competitor in EU-GMP-certified flower and extract supply to the same pharmacy channels Cantourage targets.
- Four 20 Pharma: German medical cannabis producer and distributor selling pharmaceutical-grade cannabis to pharmacies. Comparable as a domestic competitor in flower and extract supply to the same regulated German pharmacy channel.
- CannaCare Health: German medical cannabis distributor and telemedicine operator. Closely comparable to Cantourage because it combines pharmacy-channel distribution with its own doctor/patient access platform — the same hybrid model Cantourage runs via Telecan.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Cantourage social profiles
Digital presenceCantourage compliance and trust
Trust signalCompliance1 record
Cantourage financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cantourage leadership team
Management profileNumber of profiles
Profiles6 records
Cantourage subsidiaries and ownership
Company hierarchySubsidiaries1 record
Cantourage funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cantourage M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cantourage
What does Cantourage do?
Cantourage imports cannabis raw materials from over 60 cultivation partners across 18 countries, processes them at EU-GMP certified facilities in Germany and Portugal into pharmaceutical-grade products (dried flowers, extracts, dronabinol, and CBD), and distributes them to pharmacies across eight European markets under a revenue-sharing model with cultivators. The company complements its product business with patient-facing telemedicine platforms (Telecan in Germany and Cantourage Clinic in the UK) that enable online cannabis prescriptions from experienced cannabis physicians.
Is Cantourage a public or private company?
Cantourage is a public company. It is classified as public and is currently operating.
When was Cantourage founded?
Cantourage was founded in 2019. It employs 11 to 50 people.
Where is Cantourage based?
Cantourage is headquartered in Berlin, Germany, in the Europe region.
How does Cantourage make money?
Three revenue lines are on record. Cannabis flower processing and distribution is the primary driver. The others are extracts, Dronabinol and CBD and exclusive distribution partnerships.
Who are Cantourage's main competitors?
Broad incumbents on record are Canopy Growth, STADA Arzneimittel, Aurora Cannabis and Tilray Brands. Direct peers are Avextra, Sanity Group, Cannamedical Pharma, Demecan, Four 20 Pharma and CannaCare Health.
Does Cantourage have an API?
No public API is recorded for Cantourage.
What industry is Cantourage in?
Cantourage's product category is Medical Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of CRANAGAG, Medical Cannabis Delivery & Online Ordering. Its NAICS code is 42421 and its SIC code is 5122.